 |
| |
 R&D Innovation & Strategies –Integrated Strategies To Over Come Pitfalls, Enhance Drug Discovery, Overcome Attrition & New Prediction Tools That Drive Clear Decision Making.
Focused Sirna Screens In Disease Based Assays - The Fast Track To A Target
Non-Invasive, Label-Free Assays - Getting the Most Out of your Targets and a Handle on Off-Target Effects
In Silico Innovation To Solve Drug Discovery – In-Silico Data, Data Mining, Predictive Modeling,
Partnerships, Alliances & Outsourcing –Successful Partnerships, Managing Alliances, Balancing Conflicting Interests, Biotech Technology Platforms
Exploring the impact & success rate of HTS Compound Library Screening.
Intergration of technologies & applications to bridge the gap between discovery, validation & development
How do you create intelligence from all this data, both structured and unstructured, across the entire value chain?
Streamline data processes and integration whilst improving early decision making and lowering attrition through the benefit of developing a dynamic workflows and an efficient infrastructure.
“An innovative approach”-lean/ 6-sigma efforts and organisational structures supporting lead optimisation."
Alternative cost effective screening methods and techniques to strengthen assay effectively. Bringing in-vitro screening for HTS, hit optimisation & lead optimisation together.
|
|
|
 |
|
| |
|
| |
SCREENING REVOLUTIONIZED AND RE-THINKING ASSAY DEVELOPMENT
Insights into alternative cost effective screening approaches and revolutionary technology and techniques to empower
your assay realm. |
|
| |
DR HARSUKH PARMAR
Global Head of Early
Clinical Development,
ASTRAZENECA |
|
|
CARLES CALLOL B.S.
SCIENTIFIC
DIRECTOR
BIOBIDE |
|
|
LUTZ JERMUTUS, PH.D.
Senior Director,Technology
MEDIMMUNE, |
| |
|
|
DR. STEVEN VAN
HELDEN
DIRECTOR HTS &
TECHNOLOGY,
SCHERING-PLOUGH |
|
|
|
| |
SCREENING REVOLUTIONIZED & ASSAY DEVELOPMENT |
|
|
| |
Scripps Research Institute
Development and Optimization of Novel RNAi
Therapeutics Platforms Pressing the genetic off switch! RNA-mediated
long-term epigenetic silencing in human cells". |
|
| |
Create a platform for innovation: cell based assay technology,
comprehensive solutions and support that complement sophisticated
processes, “Examining Robust Assay Development Strategies to Meet
Requirements for Functional Screens ” |
|
| |
Explore Fragment Based screening collaborative Techniques,
Combining NMR, Biochemical & crystallography.“
An integrated approach” = to achieve a better verdict.
Examining X-ray crystallography, NMR and thermal |
|
| |
“INNOVATION SPOTLIGHT: REVOLUTIONARY SCREENING TECHNIQUES
Introducing alternative service-screening concepts into the market to
solve major challenges in the:
1) Low ratio of compounds that become drugs
2) High costs of new drug discovering process |
|
|
Lead Generation, Optimisation
and Characterisation
Hugh diverse compound libraries are now well-characterized and well-managed. However there are
still great gaps in our knowledge of chemical space, and problems in generating leads with the required
properties and activity.
Sessions Insights:
1. Compound library design and optimisation
2. High throughput screening in target assays vs. phenotypic assays on focused libraries
3. Fragment-based lead discovery
4. Lead discovery for lesstractable targets
5. Off-target effects |
|
|
|
|
|
|
